HMTXF 0.10 Hemostemix Inc.
| Range: | 0.024-0.079 | Vol Avg: | 16837 | Last Div: | 0 | Changes: | 0 |
| Beta: | 0.2 | Cap: | 0.00B | Currency: | USD | Exchange: | PNK |
| Sector: | Healthcare | IPO: | Thu Jan 07 2016 | Empoloyees: | |||
| CUSIP: | CIK: | ISIN: | CA4236943060 | Country: | CA | ||
| CEO: | Mr. Thomas A. Smeenk B.A., BA Hons | Website: | https://www.hemostemix.com | ||||
Hemostemix Inc., a biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of critical limb ischemia in Canada and the United States, as well as for the treatment of heart and peripheral arterial diseases. The company is also developing various types of cell products, such as synergetic cell populations and neural cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.
Stock Details
Positive 0.35
Hemostemix's Private Placement
Calgary, Alberta--(Newsfile Corp. - October 11, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC P...
newsfilecorp.com·Fri Oct 11 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow